Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice

Cancer Research

Volumn 58, Issue 23, 1998, Pages 5301-5304

  Mokyr, Margalit B ^a   Kalinichenko, Tatiana ^a   Gorelik, Leonid ^a   Bluestone, Jeffrey A ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MELPHALAN; MONOCLONAL ANTIBODY;

ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; CANCER CHEMOTHERAPY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; IMMUNOGENICITY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; ANTINEOPLASTIC AGENTS, ALKYLATING; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; IMMUNOCONJUGATES; IMMUNOTHERAPY; MELPHALAN; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PLASMACYTOMA; SPLEEN; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0032404099     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Restifo, N. P., Esquivel, F., Asher, A. L., Stoter, H., Barth, R. J., Bennink, J. R., Mule, J. J., Yewdell, J. W., and Rosenberg, S. A. Defective presentation of endogenous antigens by a murine sarcoma: implications for the failure of an anti-tumor immune response. J. Immunol., 147: 1453-1459, 1991.
2. Allison, J. P., Hurwitz, A. A., and Leach, D. R. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr. Opin. Immunol., 7: 682-686, 1995.
3. + T cells against the wild-type tumor: correlation with antigen presentation capacity. J. Exp. Med., 175: 1423-1431, 1992.
4. Chen, L., Linsley, P. S., and Hellstrom, K. E. Costimulation of T cells for tumor immunity. Immunol. Today, 14: 483-486, 1993.
5. Gorelik, L., Prokhorova, A., and Mokyr M. B. Low-dose melphalan-induced shift in the production of a TH2-type cytokine to a TH1-type cytokine in mice bearing a large MOPC-315 tumor. Cancer Immunol. Immunother., 39: 117-126, 1994.
6. Maeurer, M. J., Martin, D. M., Castelli, C., Elder, E., Leder, G., Storkus, W. J., and Lotze, M. T. Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol. Immunother., 41: 111-121, 1995.
7. Lattime, E. C., Mastrangelo, M. J., Bagasra, O., Li, W., and Berd., D. Expression of cytokine mRNA in human melanoma tissue. Cancer Immunol. Immunother., 41: 151-156, 1995.
8. Gorelik, L., and Mokyr, M. B. Low-dose melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon-γ in the therapeutic outcome. Cancer Immunol. Immunother., 41: 363-374, 1995.
9. Yuan, L., Kuramitsu, Y., Li, Y., Kobayashi, M., and Hosokawa, M. Restoration of interleukin-2 production in tumor-bearing rats through reduction of tumor-derived transforming growth factor β by treatment with bleomycin. Cancer Immunol. Immunother., 41: 355-362, 1995.
10. Walunas, T. L., Lenschow, D. L., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., and Bluestone, J. A. CTLA-4 can function as a negative regulator of T cell activation. Immunity, 1: 405-413, 1994.
11. Krummel, M. F, and Allison, J. P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med., 182: 459-465, 1995.
12. Bluestone, J. A. Is CTLA-4 a master switch for peripheral T cell tolerance? J. Immunol., 158: 1989-1993, 1997.
13. Leach, D. R., Krummel, M. F., and Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science (Washington DC), 271: 1734-1736, 1996.
14. Yang Y-F., Zou, J-P., Wijesuriya, R., Ono, S., Walunas T., Bluestone, J., Fujiwara H., and Hamaoka, T. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res., 57: 4036-4041, 1997.
15. Hurwitz, A. A., Yu, T. F-Y., Leach D. R., and Allison J. P. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA, 95: 10067-10071, 1998.
16. + T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy. Cancer Res., 50: 7641-7649, 1990.
17. + T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor. Cancer Res., 49: 4597-4606, 1989.
18. Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., and Sharpe, A. H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity, 3: 541-547, 1995.
19. Walunas, T. L., and Bluestone, J. A. CTLA-4 regulates tolerance induction and T cell differentiation in vivo. J. Immunol., 160: 3855-3860, 1998.
20. McCoy, K., Camberis, M., and Le Gros, G. Protective immunity to nematode infection is induced by CTLA-4 blockade. J. Exp. Med., 186: 183-187, 1997.